$NTRA
Natera, Inc. Stock $ntra

$ntra Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000155837023002460 Filed on March 01, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$241.8M	$217.3M	$820.2M
YoY Change	24.53%	25.56%	31.13%
Cost Of Revenue	$148.1M	$127.3M	$456.3M
YoY Change	43.51%	35.24%	43.29%
Gross Profit	$93.63M	$89.96M	$364.0M
YoY Change	2.99%	14.01%	18.53%
Gross Profit Margin	38.73%	41.41%	44.37%
Selling, General & Admin	$149.6M	$143.8M	$588.6M
YoY Change	1.35%	-2.0%	15.18%
% of Gross Profit	159.8%	159.87%	161.72%
Research & Development	$82.31M	$87.91M	$316.4M
YoY Change	2.35%	22.42%	19.76%
% of Gross Profit	87.9%	97.72%	86.94%
Depreciation & Amortization	$5.077M	$3.930M	$16.70M
YoY Change	69.12%	31.22%	48.41%
% of Gross Profit	5.42%	4.37%	4.59%
Operating Expenses	$231.9M	$231.7M	$905.0M
YoY Change	1.7%	6.02%	16.74%
Operating Profit	-$138.3M	-$141.8M	-$541.0M
YoY Change	0.85%	1.51%	15.56%
Interest Expense	$3.061M	-$2.752M	$9.319M
YoY Change	46.67%	32.37%	12.21%
% of Operating Profit
Other Income/Expense, Net	$4.585M	$2.373M	$3.538M
YoY Change	472.41%	106.17%	-34.25%
Pretax Income	-$136.8M	-$142.2M	-$546.8M
YoY Change	-1.18%	1.11%	16.07%
Income Tax	$160.0K	$421.0K	$1.000M
% Of Pretax Income
Net Earnings	-$136.9M	-$142.6M	-$547.8M
YoY Change	-1.23%	1.43%	16.13%
Net Earnings / Revenue	-56.63%	-65.63%	-66.79%
Basic Earnings Per Share	-$1.23		-$5.57
Diluted Earnings Per Share	-$1.23	-$1.37	-$5.57
COMMON SHARES
Basic Shares Outstanding	113.3M	97.60M	98.41M
Diluted Shares Outstanding	111.8M		98.41M

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$812.0M	$898.3M	$898.3M
YoY Change	7.99%	-1.75%	-1.75%
Cash & Equivalents	$403.2M	$466.0M	$466.0M
Short-Term Investments	$408.9M	$432.3M	$432.3M
Other Short-Term Assets	$29.99M	$33.72M	$33.72M
YoY Change	-15.19%	12.88%	12.88%
Inventory	$40.68M	$35.41M	$35.41M
Prepaid Expenses
Receivables	$246.8M	$244.4M	$244.4M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$1.129B	$1.212B	$1.212B
YoY Change	15.23%	10.86%	10.86%
LONG-TERM ASSETS
Property, Plant & Equipment	$100.6M	$92.45M	$164.3M
YoY Change	28.36%	41.12%	31.96%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$19.29M	$18.33M	$18.33M
YoY Change	-11.02%	-2.6%	-2.6%
Total Long-Term Assets	$189.4M	$182.7M	$182.7M
YoY Change	15.19%	27.42%	27.42%
TOTAL ASSETS
Total Short-Term Assets	$1.129B	$1.212B	$1.212B
Total Long-Term Assets	$189.4M	$182.7M	$182.7M
Total Assets	$1.319B	$1.394B	$1.394B
YoY Change	15.22%	12.78%	12.78%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$36.12M	$31.15M	$31.15M
YoY Change	99.91%	14.49%	14.49%
Accrued Expenses	$143.6M	$169.3M	$169.3M
YoY Change	9.68%	47.38%	47.38%
Deferred Revenue	$16.58M	$10.78M
YoY Change	19.15%	45.56%
Short-Term Debt	$80.40M	$80.40M	$80.35M
YoY Change	60.48%	60.63%	60.53%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$291.0M	$310.5M	$310.5M
YoY Change	25.92%	41.81%	41.81%
LONG-TERM LIABILITIES
Long-Term Debt	$282.0M	$281.7M	$281.7M
YoY Change	0.45%	0.45%	0.45%
Other Long-Term Liabilities	$95.37M	$96.58M	$96.58M
YoY Change	3667.88%	6429.95%	15.2%
Total Long-Term Liabilities	$377.3M	$378.2M	$378.2M
YoY Change	14808.65%	25473.43%	3.84%
TOTAL LIABILITIES
Total Short-Term Liabilities	$291.0M	$310.5M	$310.5M
Total Long-Term Liabilities	$377.3M	$378.2M	$378.2M
Total Liabilities	$668.3M	$688.7M	$688.7M
YoY Change	10.95%	18.1%	18.1%
SHAREHOLDERS EQUITY
Retained Earnings	-$2.100B	-$1.900B
YoY Change	40.0%	36.22%
Common Stock	$2.742B	$2.665B
YoY Change	31.21%	29.96%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$650.6M	$705.7M	$705.7M
YoY Change
Total Liabilities & Shareholders Equity	$1.319B	$1.394B	$1.394B
YoY Change	15.22%	12.78%	12.78%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$136.9M	-$142.6M	-$547.8M
YoY Change	-1.23%	1.43%	16.13%
Depreciation, Depletion And Amortization	$5.077M	$3.930M	$16.70M
YoY Change	69.12%	31.22%	48.41%
Cash From Operating Activities	-$80.89M	-$81.13M	-$431.5M
YoY Change	-41.08%	-17.83%	28.72%
INVESTING ACTIVITIES
Capital Expenditures	$11.60M	$11.83M	$47.70M
YoY Change	-26.99%	-188.99%	16.25%
Acquisitions
YoY Change
Other Investing Activities	$27.25M	$33.74M	$378.0M
YoY Change	-87.78%	-63.64%	-342.95%
Cash From Investing Activities	$15.65M	$21.92M	$330.3M
YoY Change	-92.44%	-72.43%	-260.99%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.301M	468.2M	482.6M
YoY Change	-44.63%	5398.21%	-16.24%
NET CHANGE
Cash From Operating Activities	-80.89M	-81.13M	-431.5M
Cash From Investing Activities	15.65M	21.92M	330.3M
Cash From Financing Activities	2.301M	468.2M	482.6M
Net Change In Cash	-62.94M	409.0M	381.5M
YoY Change	-185.15%	-3916.02%	966.8%
FREE CASH FLOW
Cash From Operating Activities	-$80.89M	-$81.13M	-$431.5M
Capital Expenditures	$11.60M	$11.83M	$47.70M
Free Cash Flow	-$92.49M	-$92.95M	-$479.2M
YoY Change	-39.61%	8.79%	27.36%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-5.57
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-5.21
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.84
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	98408000
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	90558000
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	81011000
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	98408000
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	90558000
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	81011000
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-5.57
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-5.21
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.84
CY2022	dei	Entity Small Business EntitySmallBusiness	false
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	95140000
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	111255000
CY2022Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	01-0894487
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001604821
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2021Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent
CY2022Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y6M10D
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	111255000
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-37478
CY2022	dei	Entity Registrant Name EntityRegistrantName	NATERA, INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2020	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	7114000
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Auditor Firm AuditorFirmId	42
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020	ntra	Cumulative Effect Of New Accounting Principle In Period Of Adoption Duration CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoptionDuration	-404000
CY2022	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2020	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	1354000
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	13011 McCallen Pass
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Building A Suite 100
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Austin
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	TX
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	78753
CY2022	dei	City Area Code CityAreaCode	650
CY2022	dei	Local Phone Number LocalPhoneNumber	980-9190
CY2022	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2022	dei	Trading Symbol TradingSymbol	NTRA
CY2022Q2	dei	Entity Public Float EntityPublicFloat	2570000000
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	113285675
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	750000000
CY2022	dei	Auditor Location AuditorLocation	San Mateo, California
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	466005000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	84386000
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	86000
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	228000
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	432301000
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	829896000
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	3830000
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	2429000
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	244385000
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	122074000
CY2022Q4	us-gaap	Inventory Net InventoryNet	35406000
CY2021Q4	us-gaap	Inventory Net InventoryNet	26909000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	33634000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	29645000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	1211817000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	1093138000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	92453000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	65516000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	71874000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	59013000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	18330000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	18820000
CY2022Q4	us-gaap	Assets Assets	1394474000
CY2021Q4	us-gaap	Assets Assets	1236487000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	31148000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	27206000
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	44010000
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	40941000
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	144214000
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	93353000
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	10777000
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	7404000
CY2022Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	80350000
CY2021Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	50052000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	310499000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	218956000
CY2022Q4	us-gaap	Long Term Notes And Loans LongTermNotesAndLoans	281653000
CY2021Q4	us-gaap	Long Term Notes And Loans LongTermNotesAndLoans	280394000
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	20001000
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	21318000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	76577000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	61036000
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1479000
CY2022Q4	us-gaap	Liabilities Liabilities	688730000
CY2021Q4	us-gaap	Liabilities Liabilities	583183000
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	750000000
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	111255000
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	95140000
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	11000
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	10000
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2050417000
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2664730000
CY2020	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	3964000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1942635000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1394836000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-16362000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2287000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	705744000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	653304000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1394474000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1236487000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	820222000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	625486000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	391005000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	316415000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	264208000
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	100035000
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	588591000
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	511034000
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	303627000
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	1361262000
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	1093660000
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	607282000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-541040000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-468174000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-216277000
CY2022	us-gaap	Interest Expense InterestExpense	9319000
CY2021	us-gaap	Interest Expense InterestExpense	8305000
CY2020	us-gaap	Interest Expense InterestExpense	15082000
CY2022	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	3538000
CY2021	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	5381000
CY2020	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	7562000
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-5848000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-546821000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-471098000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-229645000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	978000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	618000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	98000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-547799000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-471716000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-229743000
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-14075000
CY2021	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-6546000
CY2020	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	3340000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-561874000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-478262000
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-226403000
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.57
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.21
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.84
CY2020	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	82873000
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	98408000
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	90558000
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	81011000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	278711000
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	23524000
CY2020	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	7114000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	50171000
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	3340000
CY2022	ntra	Other Non Cash Benefits Charges OtherNonCashBenefitsCharges	302000
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	270650000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-229743000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	486236000
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	11816000
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	13550000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	115219000
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	-6546000
CY2021	ntra	Cumulative Effect Of New Accounting Principle In Period Of Adoption Duration CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoptionDuration	-76678000
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	550822000
CY2021	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	30601000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-471716000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	653304000
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	6411000
CY2022	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	13037000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	152384000
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	-14075000
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	433192000
CY2022	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	9290000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-547799000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	705744000
CY2022	us-gaap	Profit Loss ProfitLoss	-547799000
CY2021	us-gaap	Profit Loss ProfitLoss	-471716000
CY2020	us-gaap	Profit Loss ProfitLoss	-229743000
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	16702000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	11254000
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	8613000
CY2022	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	9290000
CY2021	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	35604000
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	13770000
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	10926000
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	7834000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	152384000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	115219000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	50171000
CY2022	ntra	Inventory Reserve Adjustments InventoryReserveAdjustments	-240000
CY2021	ntra	Inventory Reserve Adjustments InventoryReserveAdjustments	628000
CY2020	ntra	Inventory Reserve Adjustments InventoryReserveAdjustments	-163000
CY2022	us-gaap	Investment Income Amortization Of Premium InvestmentIncomeAmortizationOfPremium	4837000
CY2021	us-gaap	Investment Income Amortization Of Premium InvestmentIncomeAmortizationOfPremium	7814000
CY2020	us-gaap	Investment Income Amortization Of Premium InvestmentIncomeAmortizationOfPremium	5761000
CY2022	us-gaap	Gain Loss On Investments GainLossOnInvestments	-906000
CY2021	us-gaap	Gain Loss On Investments GainLossOnInvestments	46000
CY2020	us-gaap	Gain Loss On Investments GainLossOnInvestments	105000
CY2022	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	2000
CY2021	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	11000
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1259000
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1227000
CY2020	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	149000
CY2021	ntra	Other Non Cash Benefits Charges OtherNonCashBenefitsCharges	94000
CY2020	ntra	Other Non Cash Benefits Charges OtherNonCashBenefitsCharges	-149000
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	1770000
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-156000
CY2020	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	278316000
CY2020	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	78757000
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-5848000
CY2020	ntra	Accretion Of Convertible Notes Interest Expense Debt AccretionOfConvertibleNotesInterestExpenseDebt	7048000
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	124081000
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	43353000
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	25831000
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	8257000
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	7506000
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	7474000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1196000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	249000
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	14393000
CY2022	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	6000
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	2933000
CY2020	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	60000
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	5462000
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	19222000
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-118000
CY2022	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	3069000
CY2021	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	10569000
CY2020	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	14284000
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	9377000
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	10296000
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	8993000
CY2022	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	47650000
CY2021	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	32682000
CY2020	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	10340000
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	2056000
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-44209000
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-6895000
CY2020	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	10000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-431501000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-335236000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-182512000
CY2022	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	86947000
CY2021	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	876095000
CY2020	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	685239000
CY2022	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	248482000
CY2021	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	187580000
CY2020	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	30067000
CY2022	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	216500000
CY2021	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	532910000
CY2020	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	343315000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	47697000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	41030000
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	19604000
CY2021	ntra	Payments To Acquire Assets PaymentsToAcquireAssets	8558000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	330338000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-205193000
CY2022	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	433192000
CY2021	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	550822000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-331461000
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	6411000
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	11816000
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	23524000
CY2022	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	13037000
CY2021	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	13550000
CY2022	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	30000000
CY2020	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	270650000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	482640000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	576188000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	500847000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	381477000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	35759000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-13126000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	84614000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	48855000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	61981000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	466091000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	84614000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	48855000
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	549000
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	283000
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	67000
CY2022	us-gaap	Interest Paid Net InterestPaidNet	8060000
CY2021	us-gaap	Interest Paid Net InterestPaidNet	7077000
CY2020	us-gaap	Interest Paid Net InterestPaidNet	3296000
CY2022	ntra	Purchases Of Property And Equipment In Accounts Payable And Accruals PurchasesOfPropertyAndEquipmentInAccountsPayableAndAccruals	-1940000
CY2021	ntra	Purchases Of Property And Equipment In Accounts Payable And Accruals PurchasesOfPropertyAndEquipmentInAccountsPayableAndAccruals	5173000
CY2020	ntra	Purchases Of Property And Equipment In Accounts Payable And Accruals PurchasesOfPropertyAndEquipmentInAccountsPayableAndAccruals	2781000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-547800000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1900000000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	466100000
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	432300000
CY2022Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	80400000
CY2022Q4	us-gaap	Line Of Credit Facility Remaining Borrowing Capacity LineOfCreditFacilityRemainingBorrowingCapacity	70000000.0
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="font-style:italic;font-weight:bold;margin-left:0pt;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"/>The preparation of financial statements in accordance with generally accepted accounting principles (GAAP) in the United States requires management to make estimates and assumptions about future events that affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of revenues and expenses. Significant items subject to such estimates include the allowance for doubtful accounts calculated based on the historical uncollected balances applied to current outstanding accounts receivable balances, average selling price expected to be received from insurance payors, the operating right-of-use assets and the associated lease liabilities, the average useful life for property and equipment, deferred revenues associated with unsatisfied performance obligations, accrued liability for potential refund requests, stock-based compensation, the fair value of options, income tax uncertainties, and the expected consideration to be received from contracts with customers. These estimates and assumptions are based on management's best estimates and judgment. Management regularly evaluates its estimates and assumptions using historical experience and other factors, including contractual terms and statutory limits; however, actual results could differ from these estimates and could have an adverse effect on the Company's financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"/><i style="font-style:italic;">Revenue</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"/>The total consideration which the Company expects to be entitled to from patients and insurance carriers in exchange for the Company's products is a significant estimate when the Company calculates Average Selling Price based on the contractual pricing agreed to with each insurance carrier for each test (CPT code) performed adjusted for variable consideration related to historical percent of cases allowed, historical percent of patient responsibility collected, and historical percent of contract price collected from insurance carriers. The Company uses the expected-value approach of estimating variable consideration. The Company also considers recent trends, past events not expected to recur, and future known changes such as anticipated contractual pricing changes or insurance coverages. For insurance carriers with similar reimbursement characteristics, the Company uses a portfolio approach to estimate the effects of variable consideration. The Company also applies a constraint to the estimated variable consideration when it assesses it is probable that a significant reversal in the amount of cumulative revenue may occur in future periods. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"/>When assessing the total consideration for insurance carriers and patients, a certain percentage of revenues is further constrained for estimated refunds.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"/><i style="font-style:italic;">Stock-based compensation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"/>The Company’s stock-based compensation relates to stock options, restricted stock units (“RSUs”), performance-based awards, market-based awards, and stock purchase rights under an Employee Stock Purchase Plan (“ESPP”).<span style="display:inline-block;width:10.63pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"/>Stock based compensation granted to the Company’s employees is measured at the grant date based on the fair value of the award. The fair value is recognized as expense over the requisite service period, which is generally the vesting period or estimated performance period of the respective awards. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"/>The Company uses the Black‑Scholes option‑pricing model to estimate the fair value of stock options issued to employees and non-employees. Stock-based compensation expense for stock-based awards are based on their grant date fair value. The fair value of stock option awards is recognized as compensation expense on a straight-line basis over the requisite service period in which the awards are expected to vest and forfeitures are estimated based on historical trends at the time of grant and revised as necessary. Stock option awards that include a service condition and a performance condition are considered expected to vest when the performance condition is probable of being met. The Black-Scholes model considers several variables and assumptions in estimating the fair value of stock-based awards. These variables include the per share fair value of the underlying common stock, exercise price, expected term, risk-free interest rate, expected annual dividend yield and the expected stock price volatility over the expected term. For all stock options granted, we calculate the expected term based on the weighted average actual terms of stock option awards. We determine expected volatility using the historical volatility of the stock price of similar publicly traded peer companies. The risk-free interest rate is based on the yield available on U.S. Treasury zero-coupon issues similar in duration to the expected term of the equity-settled award.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"/>The Company determines the fair value of RSUs based on the closing price of our stock price, which is listed on Nasdaq, at the date of the grant. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"/>For stock options and performance-based awards that vest upon meeting performance conditions or market conditions in combination with performance conditions, the Company derives the requisite service period from the grant date to the date it is probable that the vesting conditions will be met. For stock options with market conditions, the Company derives the requisite service period using the Monte Carlo simulation model.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"/>The Monte Carlo simulation model is used to estimate the fair value of market-based condition awards. The model requires the input of the Company's expected stock price and peer stock price volatility, the expected term of the awards, and a risk-free interest rate. Determining these assumptions requires judgment. See further discussion on the valuation assumptions used under Note 9.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"/><i style="font-style:italic;">Income Taxes</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"/>Income taxes are recorded in accordance with Financial Accounting Standards Board ASC Topic 740,<i style="font-style:italic;"> Income Taxes </i>("ASC 740"), which provides for deferred taxes using an asset and liability approach. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Tax benefits are recognized when it is more likely than not that a tax position will be sustained during an audit. Deferred tax assets are reduced by a valuation allowance if current evidence indicates that it is considered more likely than not that these benefits will not be realized. See further discussion in Note 12, <i style="font-style:italic;">Income Taxes</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"/><i style="font-style:italic;">Allowance for doubtful accounts</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"/>The allowance for doubtful accounts for trade accounts receivable and other receivables is based on the Company’s assessment of the collectability of customer accounts. The Company regularly reviews the allowance by considering factors such as historical experience, credit quality, the age of the accounts receivable balances, and current economic conditions that may affect a customer’s ability to pay.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"/>Appropriate provision has been made for lifetime expected credit losses in accordance with ASC Topic 326-20, <i style="font-style:italic;">Financial Instruments—Credit Losses</i> (“Topic 326”), for trade receivables and available-for-sale debt securities. The Company’s estimate of expected credit losses includes consideration of past events, current conditions and forecasts of future economic conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"/><i style="font-style:italic;">Inventory</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"/>Inventory is recorded at the lower of cost or net realizable value, determined on a first-in, first-out basis. The Company uses judgment to analyze and determine if the composition of its inventory is obsolete, slow-moving or unsalable and frequently reviews such determinations. A write down of specifically identified unusable, obsolete, slow-moving or known unsalable inventory in the period is first recognized by using a number of factors including product expiration dates and scrapped inventory. Any write-down of inventory to net realizable value establishes a new cost basis and will be maintained even if certain circumstances suggest the inventory is recoverable in subsequent periods. Costs associated with the write-down of inventory are recorded to cost of revenue on our consolidated statements of operations. The Company makes assumptions about future demand, market conditions and the release of new products that may supersede older products. However, if actual market conditions are less favorable than anticipated, additional inventory write-downs may be required.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"/><i style="font-style:italic;">Investments and financial instruments</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"/><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"/>The Company classifies its investments as Level 1 or 2 within the fair value hierarchy. Fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets that the Company has the ability to access. Fair values determined by Level 2 inputs utilize data points that are observable such as quoted prices, interest rates and yield curves. The Company holds Level 2 securities which are initially valued at the transaction price and subsequently valued by a third-party service provider using inputs other than quoted prices that are observable either directly or indirectly, such as yield curve, volatility factors, credit spreads, default rates, loss severity, current market and contractual prices for the underlying instruments or debt, broker and dealer quotes, as well as other relevant economic measures. The Company performs certain procedures to corroborate the fair value of these holdings. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;visibility:hidden;background:#ffff00;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"/><i style="font-style:italic;">Right-of-use assets</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"/>The incremental borrowing rate is used to determine the present value of the minimum future lease payments. The Company estimates the incremental borrowing rate of its leases based on corporate bonds with a similar credit rating as the Company and a similar bond term as the lease term as of the approximate lease commencement date. The Company calculates the weighted-average annual percentage yield of bonds with a similar credit rating and term to determine the incremental borrowing rate. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"/><i style="font-style:italic;">Property and equipment</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"/><span style="font-style:italic;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"/>Property and equipment, including purchased and internally developed software, are stated at cost. Depreciation and amortization is calculated using the straight-line method over the estimated useful lives of the assets, which are generally three to five years determined by the classification of the property and equipment class in accordance with the Company’s fixed asset policy. Leasehold improvements are amortized using the straight-line method over the estimated useful lives of the assets or the remaining term of the lease, whichever is shorter. The Company periodically reviews the useful lives assigned to property and equipment placed in service in accordance with the Company’s fixed asset policy and changes the estimates of useful lives to reflect the results of such reviews. The Company amortizes its internal-use software over the estimated useful lives of <span style="-sec-ix-hidden:Hidden_j9dCPjBIYEuP7MqYE-fQ6A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three years</span></span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"/><i style="font-style:italic;">Other accrued liabilities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"/>The Company uses estimates, judgments, and assumptions to determine liabilities primarily related to refunds reserve, tax-related liabilities, payroll and related expenses, marketing liabilities, clinical trials and other operating expenses. Estimates consist of historical trends, analytical procedures, review of supporting documentation, inquiries with supply partners and vendors, and other relevant assumptions. Estimates are used in several areas including, but not limited to, estimates of progress to date for certain contacts with vendors, liabilities related to clinical trials, reserves associated with insurance and general overpayments, and the provision for income taxes. Although the Company believe its estimates, assumptions, and judgment are reasonable, it is based upon information presently available and are subject to change.</p>
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	466005000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	84386000
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	86000
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	228000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	466091000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	84614000
CY2021Q4	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	4000000.0
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.0173
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Risk and Uncertainties</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="font-style:italic;font-weight:bold;margin-left:0pt;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Financial instruments that potentially subject the Company to credit risk consist of cash, accounts receivable and investments. The Company limits its exposure to credit loss by placing its cash in financial institutions with high credit ratings. The Company's cash may consist of deposits held with banks that may at times exceed federally insured limits. The Company performs evaluations of the relative credit standing of these financial institutions and limits the amount of credit exposure with any one institution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">For the years ended December 31, 2022, 2021, and 2020, there were no customers exceeding 10% of total revenues on an individual basis. As of December 31, 2022 and 2021, there were no customers with an outstanding balance exceeding 10% of net accounts receivable.</p>
CY2022	us-gaap	Advertising Expense AdvertisingExpense	1800000
CY2021	us-gaap	Advertising Expense AdvertisingExpense	2200000
CY2020	us-gaap	Advertising Expense AdvertisingExpense	600000
CY2022Q4	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	5900000
CY2021Q4	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	2300000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2287000
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	4259000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-16362000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2287000
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	3949000
CY2022	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	248500000
CY2021	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	187600000
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	200000
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	200000
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	900000
CY2020	us-gaap	Inventory Write Down InventoryWriteDown	200000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	820222000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	625486000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	391005000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	820222000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	625486000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	391005000
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	244385000
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	122074000
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	10777000
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	7404000
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	20001000
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	21318000
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	30778000
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	28722000
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	28722000
CY2020Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	72930000
CY2022	ntra	Contract With Customer Liability Additions ContractWithCustomerLiabilityAdditions	28978000
CY2021	ntra	Contract With Customer Liability Additions ContractWithCustomerLiabilityAdditions	7915000
CY2022	ntra	Contract With Customer Liability Noncurrent Reclassification To Current ContractWithCustomerLiabilityNoncurrentReclassificationToCurrent	-337000
CY2021	ntra	Contract With Customer Liability Noncurrent Reclassification To Current ContractWithCustomerLiabilityNoncurrentReclassificationToCurrent	-10080000
CY2022	us-gaap	Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Measure Of Progress ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress	-8782000
CY2021	us-gaap	Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Measure Of Progress ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress	-37784000
CY2022	us-gaap	Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized	-17803000
CY2021	us-gaap	Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized	-4259000
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	30778000
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	28722000
CY2022	us-gaap	Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Measure Of Progress ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress	-8800000
CY2022	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	17800000
CY2022	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	900000
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Number Of Positions DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions	61
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	430800000
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	35048000
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	692000
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	395746000
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	15411000
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	430794000
CY2022Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	16103000
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	329499000
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	320708000
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	118904000
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	111593000
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis	448403000
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Single Maturity Date AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate	432301000
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	2429000
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	4220000
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	2919000
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	1770000
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-156000
CY2020	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	1354000
CY2022	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	369000
CY2021	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	1635000
CY2020	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	457000
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	3830000
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	2429000
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	4220000
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	128151000
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	84929000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	35698000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.0072
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	19413000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	92453000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	65516000
CY2022	us-gaap	Depreciation Depreciation	16700000
CY2021	us-gaap	Depreciation Depreciation	11300000
CY2022	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	41900000
CY2022Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	2930000
CY2021Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	2567000
CY2022Q4	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	11821000
CY2021Q4	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	15726000
CY2022Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	20426000
CY2021Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	15854000
CY2022Q4	us-gaap	Other Employee Related Liabilities Current OtherEmployeeRelatedLiabilitiesCurrent	8833000
CY2021Q4	us-gaap	Other Employee Related Liabilities Current OtherEmployeeRelatedLiabilitiesCurrent	6794000
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	44010000
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	40941000
CY2022Q4	us-gaap	Accrued Insurance Current And Noncurrent AccruedInsuranceCurrentAndNoncurrent	18948000
CY2021Q4	us-gaap	Accrued Insurance Current And Noncurrent AccruedInsuranceCurrentAndNoncurrent	17210000
CY2022Q4	ntra	Accrued Charges For Outsourced Testing AccruedChargesForOutsourcedTesting	17036000
CY2021Q4	ntra	Accrued Charges For Outsourced Testing AccruedChargesForOutsourcedTesting	5849000
CY2022Q4	ntra	Accrued Testing And Laboratory Materials From Suppliers AccruedTestingAndLaboratoryMaterialsFromSuppliers	13281000
CY2021Q4	ntra	Accrued Testing And Laboratory Materials From Suppliers AccruedTestingAndLaboratoryMaterialsFromSuppliers	3799000
CY2022Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	8943000
CY2021Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	7853000
CY2022Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	36710000
CY2021Q4	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	11758000
CY2022Q4	ntra	Accrued Shipping Charges AccruedShippingCharges	485000
CY2021Q4	ntra	Accrued Shipping Charges AccruedShippingCharges	969000
CY2022Q4	us-gaap	Sales And Excise Tax Payable Current And Noncurrent SalesAndExciseTaxPayableCurrentAndNoncurrent	4319000
CY2021Q4	us-gaap	Sales And Excise Tax Payable Current And Noncurrent SalesAndExciseTaxPayableCurrentAndNoncurrent	2230000
CY2022Q4	ntra	Accrued Specimen Service Fees AccruedSpecimenServiceFees	6631000
CY2021Q4	ntra	Accrued Specimen Service Fees AccruedSpecimenServiceFees	13442000
CY2022Q4	ntra	Accrued Clinical Trials And Studies AccruedClinicalTrialsAndStudies	23301000
CY2021Q4	ntra	Accrued Clinical Trials And Studies AccruedClinicalTrialsAndStudies	11218000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	7639000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5752000
CY2022Q4	ntra	Accrued Fixed Asset Purchases AccruedFixedAssetPurchases	1821000
CY2021Q4	ntra	Accrued Fixed Asset Purchases AccruedFixedAssetPurchases	1853000
CY2022Q4	ntra	Accrued Interest AccruedInterest	1078000
CY2021Q4	ntra	Accrued Interest AccruedInterest	1078000
CY2022Q4	ntra	Other Accrued Sundry Expenses Current OtherAccruedSundryExpensesCurrent	4022000
CY2021Q4	ntra	Other Accrued Sundry Expenses Current OtherAccruedSundryExpensesCurrent	10342000
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	144214000
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	93353000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	16007000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	16352000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	16732000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	13676000
CY2021Q4	us-gaap	Accrued Insurance Current And Noncurrent AccruedInsuranceCurrentAndNoncurrent	17210000
CY2020Q4	us-gaap	Accrued Insurance Current And Noncurrent AccruedInsuranceCurrentAndNoncurrent	17366000
CY2022	ntra	Insurance Carrier Reserves Additions InsuranceCarrierReservesAdditions	23718000
CY2021	ntra	Insurance Carrier Reserves Additions InsuranceCarrierReservesAdditions	16340000
CY2022	ntra	Insurance Refunds To Carriers InsuranceRefundsToCarriers	14558000
CY2021	ntra	Insurance Refunds To Carriers InsuranceRefundsToCarriers	10784000
CY2022	ntra	Insurance Carrier Reserves Released InsuranceCarrierReservesReleased	7422000
CY2021	ntra	Insurance Carrier Reserves Released InsuranceCarrierReservesReleased	5712000
CY2022Q4	us-gaap	Accrued Insurance Current And Noncurrent AccruedInsuranceCurrentAndNoncurrent	18948000
CY2021Q4	us-gaap	Accrued Insurance Current And Noncurrent AccruedInsuranceCurrentAndNoncurrent	17210000
CY2022	ntra	Noncash Investing Activities Related To Right Of Use Assets NoncashInvestingActivitiesRelatedToRightOfUseAssets	22100000
CY2021	ntra	Noncash Investing Activities Related To Right Of Use Assets NoncashInvestingActivitiesRelatedToRightOfUseAssets	44400000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	7639000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	76577000
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	84216000
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.067
CY2022	us-gaap	Lease Cost LeaseCost	13800000
CY2021	us-gaap	Lease Cost LeaseCost	10900000
CY2020	us-gaap	Lease Cost LeaseCost	7800000
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	9400000
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	10300000
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	9000000.0
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	12443000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	33992000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	109202000
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	24986000
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	84216000
CY2022Q4	us-gaap	Recorded Unconditional Purchase Obligation RecordedUnconditionalPurchaseObligation	78353000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	5039000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	711000
CY2020	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	278300000
CY2020	us-gaap	Repayments Of Debt RepaymentsOfDebt	79200000
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	287500000
CY2022Q4	ntra	Debt Instrument Unamortized Debt Discount And Debt Issuance Cost DebtInstrumentUnamortizedDebtDiscountAndDebtIssuanceCost	5847000
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.0465
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	281653000
CY2020Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4791665
CY2020Q3	us-gaap	Share Price SharePrice	60
CY2020Q3	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	300000
CY2020Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	271000000.0
CY2021Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5175000
CY2021Q3	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	113
CY2021Q3	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	400000
CY2021Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	551200000
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13144500
CY2022Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	35
CY2022Q4	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	500000
CY2022Q4	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	433200000
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	750000000
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	111255000
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-114832000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-98931000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-48226000
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-21676000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.0396
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-29206000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.0620
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-10672000
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	7024000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.0128
CY2021	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	9193000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.0195
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-46128000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.0980
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-23791000
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.1036
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	332000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.0006
CY2021	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	167000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.0004
CY2020	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	55000
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.0002
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	1964000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0.0036
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	344000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0.0007
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	792000
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0.0035
CY2022	ntra	Income Tax Reconciliation Nondeductible Officers Compensation IncomeTaxReconciliationNondeductibleOfficersCompensation	4883000
CY2022	ntra	Effective Income Tax Reconciliation Nondeductible Officers Compensation EffectiveIncomeTaxReconciliationNondeductibleOfficersCompensation	0.0089
CY2021	ntra	Income Tax Reconciliation Nondeductible Officers Compensation IncomeTaxReconciliationNondeductibleOfficersCompensation	24387000
CY2021	ntra	Effective Income Tax Reconciliation Nondeductible Officers Compensation EffectiveIncomeTaxReconciliationNondeductibleOfficersCompensation	0.0518
CY2020	ntra	Income Tax Reconciliation Nondeductible Officers Compensation IncomeTaxReconciliationNondeductibleOfficersCompensation	8984000
CY2020	ntra	Effective Income Tax Reconciliation Nondeductible Officers Compensation EffectiveIncomeTaxReconciliationNondeductibleOfficersCompensation	0.0391
CY2022	ntra	Income Tax Reconciliation Acquisition Costs IncomeTaxReconciliationAcquisitionCosts	3226000
CY2022	ntra	Effective Income Tax Reconciliation Acquisition Costs EffectiveIncomeTaxReconciliationAcquisitionCosts	0.0059
CY2021	ntra	Income Tax Reconciliation Acquisition Costs IncomeTaxReconciliationAcquisitionCosts	8901000
CY2021	ntra	Effective Income Tax Reconciliation Acquisition Costs EffectiveIncomeTaxReconciliationAcquisitionCosts	0.02
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	130156000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.2380
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	150277000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.3190
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	76920000
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.3350
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	978000
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0018
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	618000
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0013
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	98000
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0004
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1000000.0
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1000000.0
CY2022	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	600000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	600000
CY2021	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	300000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	100000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	358109000
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	315552000
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	4068000
CY2021Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	4443000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	52319000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	38725000
CY2022Q4	ntra	Deferred Tax Assets Capitalized Research Costs DeferredTaxAssetsCapitalizedResearchCosts	59128000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	22781000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	14098000
CY2022Q4	ntra	Deferred Tax Assets Lease Liabilities DeferredTaxAssetsLeaseLiabilities	21000000
CY2021Q4	ntra	Deferred Tax Assets Lease Liabilities DeferredTaxAssetsLeaseLiabilities	16843000
CY2022Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	5094000
CY2021Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	6363000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	23814000
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	15928000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	546313000
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	411952000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	526235000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	396079000
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	20078000
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	15873000
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	1219000
CY2022Q4	ntra	Deferred Tax Liabilities Right Of Use Lease Assets DeferredTaxLiabilitiesRightOfUseLeaseAssets	18859000
CY2021Q4	ntra	Deferred Tax Liabilities Right Of Use Lease Assets DeferredTaxLiabilitiesRightOfUseLeaseAssets	15873000
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	20078000
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	15873000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	526200000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	526200000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	396100000
CY2022Q4	ntra	Tax Credit Carryforward Taxable Income Required For Full Utilization Of Realizable Deferred Tax Assets TaxCreditCarryforwardTaxableIncomeRequiredForFullUtilizationOfRealizableDeferredTaxAssets	2000000000.0
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	17514000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	11500000
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	8619000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	6301000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	6017000
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	2889000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	29000
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	3000
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	8000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	23844000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	17514000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	11500000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	23800000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	17500000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	11500000
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-547799000
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-471716000
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-229743000
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	98408000
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	90558000
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	81011000
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.57
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.21
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.84
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	19998000
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	17683000
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	18343000
CY2022	dei	Auditor Name AuditorName	Ernst & Young LLP

Files In Submission

Name	View Source	Status
ntra-20221231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
ntra-20221231_lab.xml	Edgar Link	unprocessable
0001558370-23-002460-index-headers.html	Edgar Link	pending
0001558370-23-002460-index.html	Edgar Link	pending
0001558370-23-002460.txt	Edgar Link	pending
0001558370-23-002460-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
ntra-20221231.xsd	Edgar Link	pending
ntra-20221231x10k.htm	Edgar Link	pending
ntra-20221231x10k006.jpg	Edgar Link	pending
ntra-20221231xex23d1.htm	Edgar Link	pending
ntra-20221231xex31d1.htm	Edgar Link	pending
ntra-20221231xex31d2.htm	Edgar Link	pending
ntra-20221231xex32d1.htm	Edgar Link	pending
ntra-20221231xex32d2.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
ntra-20221231_cal.xml	Edgar Link	unprocessable
ntra-20221231_def.xml	Edgar Link	unprocessable
ntra-20221231x10k_htm.xml	Edgar Link	completed
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NTRA
Natera, Inc. Stock $ntra

2023 Q1 Form 10-K Financial Statement

#000155837023002460 Filed on March 01, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NTRA Natera, Inc. Stock $ntra

2023 Q1 Form 10-K Financial Statement

#000155837023002460 Filed on March 01, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NTRA
Natera, Inc. Stock $ntra